Global Targeted Drug for Blood Cancers Market Growth 2024-2030

Blood cancers (Leukemia) is a malignant clonal disease of hematopoietic stem cells. According to the degree of differentiation and maturity of leukemia cells and the natural history of the disease, leukemia is divided into two categories: acute leukemia (AL) and chronic leukemia (CL). Secondly, AL can be divided into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) based on the mainly affected cell series. CL is divided into chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML, also known as chronic myelogenous leukemia) and rare types of leukemia. In the past decade or so, targeted drugs have made many breakthrough achievements in the clinical treatment of leukemia.

Targeted drugs for blood cancers are a class of pharmaceuticals designed to specifically target and attack cancer cells while minimizing harm to healthy cells. These drugs work by interfering with specific molecules or pathways that are crucial for cancer cell growth and survival. Examples of targeted drugs for blood cancers include monoclonal antibodies, small molecule inhibitors, and immunotherapies, which may target proteins on the surface of cancer cells, enzymes involved in cell signaling pathways, or immune checkpoints. By selectively targeting cancer cells, these drugs offer the potential for more effective treatment with fewer side effects compared to traditional chemotherapy. Targeted drugs have revolutionized the treatment landscape for blood cancers, offering new options for patients and improving outcomes.

As a new trend in the treatment of leukemia, gene-targeted drugs will see more research and development in the future. Although this drug still has some problems, such as high price, drug resistance, etc., with the continuous advancement of science and technology and the continuous progress of medicine, it is believed that gene-targeted drugs will become an important means of treating leukemia.

The global Targeted Drug for Blood Cancers market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Targeted Drug for Blood Cancers Industry Forecast” looks at past sales and reviews total world Targeted Drug for Blood Cancers sales in 2023, providing a comprehensive analysis by region and market sector of projected Targeted Drug for Blood Cancers sales for 2024 through 2030. With Targeted Drug for Blood Cancers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug for Blood Cancers industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drug for Blood Cancers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Drug for Blood Cancers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug for Blood Cancers market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug for Blood Cancers and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug for Blood Cancers.

Leukemia occurs most often in adults older than 55 years, but it is the most common cancer in children younger than 15 years. Among adults, the most common types are CLL (35%) and AML (32%). Among children and teens, ALL is the most common, accounting for 75% of pediatric leukemia cases.

Globally, an estimated 440,000 new cases of leukemia are diagnosed each year along with 310,000 deaths. There will be an estimated 60,000 new cases of leukemia in the United States in 2023, and more than 24,000 related deaths. Survival rates vary substantially by leukemia subtype, ranging from a current five-year relative survival rate of 27% for adults diagnosed with AML to 86% for those with CLL, and 66% for children, adolescents, and young adults diagnosed with AML to 92% for those with ALL. In 2018, there are an estimated 381,774 people living with or in remission from leukemia in the United States. As the burden of leukemia grows, there will be a corresponding increase in the demand for effective treatment options, including targeted drugs.

The development of targeted drugs has transformed the treatment landscape for leukemia, offering improved efficacy and safety compared to traditional chemotherapy. Patients and healthcare providers increasingly prefer targeted therapies due to their ability to selectively attack cancer cells while sparing healthy tissues, leading to higher demand for these drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug for Blood Cancers market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Monoclonal Antibodies
• Small-Molecule Drugs

Segmentation by Application:

• Acute Myeloid Leukemia (AML)
• Chronic Myeloid Leukemia (CML)
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphocytic Leukemia (CLL)

This report also splits the market by region:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Novartis Pharms
• Bristol-Myers Squibb
• IL-Yang Pharms
• Pfizer
• Takeda Oncology
• Johnson & Johnson
• Gilead Sciences
• Abbvie
• Genentech
• Sanofi
• Amgen
• Roche
• GlaxoSmithKline
• AstraZeneca
• BeiGene
• Eli Lilly
• Merck

Key Questions Addressed in this Report

1. What is the 10-year outlook for the global Targeted Drug for Blood Cancers market?
2. What factors are driving Targeted Drug for Blood Cancers market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do Targeted Drug for Blood Cancers market opportunities vary by end market size?
5. How does Targeted Drug for Blood Cancers break out by Type, by Application?